Briakinumab for the treatment of plaque psoriasis

BioDrugs

Volumn 26, Issue 1, 2012, Pages 9-20

  Traczewski, Pawel ^a   Rudnicka, Lidia ^a,b,c  

^a CSK MSWiA ^*  (Poland)

^b POLISH ACADEMY OF SCIENCES   (Poland)

^c MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Briakinumab; Interleukin 12 inhibitors; Interleukin 23 inhibitors; Monoclonal antibodies; Psoriasis.

Indexed keywords

ADALIMUMAB; BRIAKINUMAB; CYTOKINE; ETANERCEPT; FOLIC ACID; INFLIXIMAB; INTERLEUKIN 12; INTERLEUKIN 23; METHOTREXATE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ARTHRALGIA; BASAL CELL CARCINOMA; COLON CANCER; CROHN DISEASE; CYTOKINE RELEASE; DIARRHEA; DISEASE SEVERITY; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; HEADACHE; HUMAN; HYPERTENSION; IMMUNE RESPONSE; INFLAMMATION; INJECTION SITE REACTION; KERATINOCYTE; MENINGIOMA; NONHUMAN; OBESITY; OUTCOMES RESEARCH; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PSORIASIS; PSORIASIS SEVERITY INDEX; PSORIASIS VULGARIS; QUALITY OF LIFE; REVIEW; RHINOPHARYNGITIS; SHORT FORM 36; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA; THORAX PAIN; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION; VISUAL ANALOG SCALE;

ANIMALS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; DERMATOLOGIC AGENTS; DRUG APPROVAL; HUMANS; INTERLEUKIN-12; INTERLEUKIN-23; PSORIASIS;

EID: 84855709124     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.2165/11595940-000000000-00000     Document Type: Review

References (46)

1. Schon MP, Boehncke WH. Psoriasis. N Engl J Med 2005; 352 (18): 1899-912 (Pubitemid 40627816)
2. Stern RS, Nijsten T, Feldman SR, et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc 2004; 9 (2): 136-9 (Pubitemid 38457271)
3. Davidson A, Diamond B. Autoimmune diseases. N Engl J Med 2001; 345 (5): 340-50
4. Langley RGB, Krueger GG, Griffiths CEM. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis 2005; 64 Suppl. 2: ii18-23 (Pubitemid 40288514)
5. Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis 2005; 64 Suppl. II: ii65-8 (Pubitemid 40288526)
6. O'Neill JL, Kalb RE. Ustekinumab in the therapy of chronic plaque psoriasis. Biologics 2009; 3: 159-68
7. Krueger GG, Langley RG, Leonardi C, et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007; 356: 580-92 (Pubitemid 46220818)
8. Scanlon JV, Exter BP, Steinberg M, et al. Treatment of adult moderate to severe chronic plaque psoriasis. Ann Pharmacother 2009; 43: 1456-65
9. Shear NH, Prinz J, Papp K, et al. Targeting the interleukin-12/23 cytokine family in the treatment of psoriatic disease. J Cutan Med Surg 2008; 12: S1-10
10. Piskin G, Sylva-Steenland RM, Bos JD, et al. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J Immunol 2006; 176: 1908-15 (Pubitemid 43134336)
11. Gandhi M, Alwawi E, Gordon KB. Anti-p40 antibodies ustekinumab and briakinumab: blockade of interleukin-12 and interleukin-23 in the treatment of psoriasis. Semin Cutan Med Surg 2010 Mar; 29 (1): 48-52
12. Ding C, Xu J, Li J. ABT-874, a fully human monoclonal anti-IL-12/IL-23 antibody for the potential treatment of autoimmune diseases. Curr Opin Investig Drugs 2008; 9 (5): 515-22 (Pubitemid 351677906)
13. Waldner MJ, Neurath MF. Novel cytokine-targeted therapies and intestinal inflammation. Curr Opinion Pharm 2009; 9: 702-7
14. Weger W. Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents. Br J Pharm 2010; 160: 810-20
15. European Medicines Agency. Abbott Laboratories Limited withdraws its marketing authorisation application for Ozespa (briakinumab) [media release]. 2011 Jan 17 [online]. Available from URL: http://www.ema.europa.eu/ema/index. jsp?curl=pages/news-and-events/news/2011/01/news-detail-001181. jsp&;mid=WC0b01ac058004d5c1&murl=menus/news-and-events/news-and-events. jsp&jsenabled=true [Accessed 2011 Sep 21]
16. Langrish CL, McKenzie BS, Wilson NJ, et al. IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol Rev 2004; 202: 96-105 (Pubitemid 39576907)
17. Hunter CA. New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat Rev Immunol 2005; 57: 521-31 (Pubitemid 40961330)
18. Kurzeja M, Rudnicka L, Olszewska M. New interleukin-23 pathway inhibitors in dermatology: ustekinumab, briakinumab, and secukinumab. Am J Clin Dermatol 2011; 12 (2): 1-13
19. Lima XT, Abuabara K, Boer Kimball A, et al. Briakinumab. Expert Opin Biol Ther 2009; 9 (8): 1107-13
20. Aggarval S, Ghilardi N, Xie MH, et al. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 2003; 278 (3): 1910-4 (Pubitemid 36801431)
21. Hong K, Chu A, Ludviksson BR, et al. IL-12, independently of IFN-gamma, plays a crucial role in the pathogenesis of murine psoriasis-like skin disorder. J Immunol 1999; 162 (12): 7480-91 (Pubitemid 29277728)
22. Neograles KE, Brasington RD, Bowcock AM. New insights into the pathogenesis and genetics of psoriatic arthritis. Nat Clin Pract Rheumatol 2009 Feb; 5 (2): 83-91
23. Krueger G, Ellis NC. Psoriasis: recent advances in understanding its pathogenesis and treatment. J Am Acad Dermatol 2005; 53 (1 Suppl. 1): S94-100
24. Lee E, Trepiccho WL, Oestreicher JL, et al. Increased expression of interleukin- 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004; 199 (1): 125-30 (Pubitemid 38076484)
25. Robertson MJ, Ritz J. Interleukin 12: basic biology and potential applications in cancer treatment. Oncologist 1996; 1 (1/2): 88-97 (Pubitemid 126669376)
26. Lyakh L, Trincheri G, Provezza L, et al. Regulation of interleukin-12/interleukin-23 production and the T-helper 17 response in humans. Immunol Rev 2008; 226: 112-31
27. Valiante NM, Rengaraju M, Trincheri G. Role of the production of natural killer cell stimulatory factor (NKSF/IL-12) in the ability of B-cell lines to stimulate T and NK cell proliferation. Cell Immunol 1992; 145 (1): 187-98
28. Kobayashi M, Fitz L, Ryan M, et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 1989; 170 (3): 827-45 (Pubitemid 19226667)
29. Jinushi M, Tahara H. Cytokine gene-mediated immunotherapy: current status and future perspectives. Cancer Sci 2009; 100 (8): 1389-9
30. Kimball AB, Gordon KB, Langley RG, et al. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebocontrolled, phase 2 trial. Arch Dermatol 2008; 144 (2): 200-7 (Pubitemid 351287002)
31. Kuus-Reichel K, Grauer LS, Karavodin LM, et al
32. Braddock M. IDDB meeting report. Ninth International Inflammation and Immune Diseases Drug Discovery and Development Annual Summit (Part II); 2005 Mar 14-15; Philadelphia (PA
33. Salfeld JG, Roguska M, Paskind M, et al. Human antibodies binding human IL-12, methods for their production, and use in IL-12-related diseases such as rheumatoid arthritis, Crohn's disease, and multiple sclerosis. World patent WO-2000056772. 2000 Sep 28
34. Mannon PJ, Fuss IJ, Mayer L, et al. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 2004; 351 (20): 2069-79 (Pubitemid 39482500)
35. Paulson S, Valdes J, Hruska M, et al. The pharmacokinetics of the fully human, interleukin-12/-23 monoclonal antibody (ABT-874) in normal healthy volunteers [abstract]. J Am Acad Dermatol 2009; 60 (3): AB168
36. Kimball AB, Gordon KB, Langley RG, et al. Efficacy and safety of ABT-874, a monoclonal anti-interleukin 12/23 antibody, for the treatment of chronic plaque psoriasis: 36-week observation/retreatment and 60-week open-label extension phases of a randomized phase II trial. JAmAcad Dermatol 2011; 64 (2): 263-74
37. Gordon K, Langley R, Gottlieb A, et al. Efficacy and safety results from a phase III, randomized controlled trial comparing two dosing regimens of abt-874 to placebo in patients with moderate to severe psoriasis [abstract P068]. J Eur Acad Dermatol Venereol 2010; 24 Suppl. 4: 30
38. Gottlieb A, Leonardi C, Kerdel F, et al. Efficacy and safety of briakinumab versus etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol 2011 Sep; 165 (3): 652-60
39. Strober BE, Crowley J, Yamauchi P, et al. Efficacy and safety results from a phase III, randomised controlled trial comparing the safety and efficacy of briakinumab to etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol 2011 Sep; 165 (3): 661-8
40. Abbott. Abbott reports psoriasis phase III results of its investigational IL-12/23 inhibitor briakinumab (ABT-874) [media release]. 2010 Oct 11 [online]. Available from URL: http://www.abbott.com/global/url/pressRelease/en-US/60.5:5/ Press-Release-0909.htm [Accessed 2011 Sep 21]
41. Reich K, Langley R, Papp K, et al. Efficacy and safety of ABT-874 versus methotrexate in patients with moderate to severe psoriasis [abstract]. 19th EADV Congress; 2010 Oct 6-10; Gothenburg
42. Traczewski P, Rudnicka L. Adalimumab in dermatology. Br J Clin Pharmacol 2008; 66 (5): 618-25
43. Papp K, Signorovitch J, Yang H, et al. Psoriasis treatment with ABT-874 Effects on health-related quality of life and work productivity and activity impairment [abstract]. 19th EADV Congress; 2010 Oct 6-10; Gothenburg
44. Menter A, Signorovitch J, Parikh K, et al. ABT-874 versus etanercept or placebo treatment for moderate to severe psoriasis health-related quality of life outcomes [abstract]. 19th EADV Congress; 2010 Oct 6-10; Gothenburg
45. Caspi A. Clinical trials, research, and FDA findings. Biotechnol Healthc 2011 Spring; 8 (1): 5-6
46. Krauskopf L. Both U.S., EU applications withdrawn for briakinumab [media release]. Reuters 2011 Jan 14 [online]. Available from URL: http://www. reuters.com/article/2011/01/14/abbottlaboratories-idUKN1415033420110114 [Accessed 2011 Oct 10]